Patients Stopping Anti-Obesity Injections Put On Pounds Far More Rapidly Compared to Dieters

A recent study suggests that people who discontinue new slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise plans.

Findings released in a prominent medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while using the jabs, the mass returns at an average rate of nearly a kilo each month upon discontinuation.

"People buying these drugs need to be informed of the risk of fast rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.

Such speed of regain means a reversion to starting mass in about 18 months.

Comparing Treatments

The analysis, which examined dozens of studies involving thousands of patients, compared the results of the injectable medications with other pills.

Scientists emphasize that individuals who lose weight through lifestyle changes alone generally see a more gradual creep back—around 100 grams monthly—after stopping.

Understanding the Rapid Regain

Doctors believe the mode of action of the jabs explains the amplified regain.

These medications mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.

"Sustained high doses of the hormone concentrations far above than the body's typical production may cause the body to produce less of its endogenous hormone, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.

"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating a significant risk."

A Chronic Disease?

Health authorities advise the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.

Many experts contend that, due to the significant potential of relapse, the treatment might need to be ongoing.

This perspective is reinforced by drug manufacturers, who note that the findings "emphasize the chronic nature of excess weight," similar to managing diseases like diabetes.

User Testimonies

Users who have stopped the medication describe a powerful resurgence of cravings.

"It was like a switch that goes on and I was suddenly ravenous," described a patient.

The struggle is exacerbated if users have not developed permanent lifestyle or habit modifications during treatment.

Significant Adoption

Survey data show that a significant number of people in the UK have tried these injections in the last 12 months, with interest being substantial.

• Adoption is higher among females than men.
• The 40s and 50s age group shows the greatest level of interest.
• Many access the drugs through private healthcare rather than public health services.

In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent cure and lasting health benefits relies on ongoing lifestyle management.